Recombinant adeno-associated virus (rAAV) is a key vector in delivering therapeutic genes for genetic disorders. To optimize clinical efficacy, the ratio of ‘full’ to ’empty’ viral particles must be balanced. Mass photometry revolutionizes this process by precisely measuring and analyzing these particles, ensuring a more effective gene therapy production workflow. With this advancement, researchers can streamline the manufacturing of gene therapy vectors, leading to potential improvements in patient outcomes and treatment accessibility. Mass photometry offers a promising solution to enhance the quality and efficiency of gene therapy manufacturing, ultimately benefiting individuals with genetic disorders in need of effective treatments.
Read more from miragenews.com
